Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2021 | $4.00 → $3.00 | Buy | HC Wainwright & Co. |
Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied
Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
20-F - Check-Cap Ltd (0001610590) (Filer)
HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously
Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00
HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex
IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan
Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin
Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental. Symetryx discusses its concerns around the actions of the Board in its evaluation
ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)
SC 13D - Check-Cap Ltd (0001610590) (Subject)
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)